Leukemia

Latest News

In the phase 1b/2 FELIX study, obecabtagene autoleucel was associated with low incidence of grade 3 or higher immune-related toxicity.
Obe-cel Elicits Durable Responses in Relapsed/Refractory B-Cell ALL

December 21st 2024

In the phase 1b/2 FELIX study, obecabtagene autoleucel was associated with low incidence of grade 3 or higher immune-related toxicity.

Bezuclastinib Demonstrates Improved Symptoms in Systemic Mastocytosis
Bezuclastinib Demonstrates Improved Symptoms in Systemic Mastocytosis

December 16th 2024

From 2013 to 2022, the rate of important identified risks associated with ponatinib in the treatment of those with ALL or CML had decreased.
Ponatinib-Related Toxicity Management in ALL/CML Improves Over Time

December 14th 2024

Improved OS in Leukemia Elicited by cBTK and BCL2 inhibitors and anti-CD20 Antibodies
Improved OS in Leukemia Elicited by cBTK and BCL2 inhibitors and anti-CD20 Antibodies

December 12th 2024

Notable Clinical Benefit and Safety Data with IO-202 Plus Azacitidine in CMML
Notable Clinical Benefit and Safety Data with IO-202 Plus Azacitidine in CMML

December 12th 2024